IL17A and tuberculosis: Contrary to the many cases of tuberculosis reactivation during treatment with TNF-α inhibitors and a few cases associated with IL-12/23 inhibitors, there have been no reported cases in patients exposed to IL-17 or IL-23 inhibitors both in clinical and real-world settings, which was consistent with our results [14,28,29,30,31].